Morgan Bayer

Key 2024 SABCS and ASH findings: palbociclib improves PFS in HR+, HER2+ breast cancer, cilta-cel achieves 100% CR in smoldering MM, and selinexor with ruxolitinib aids myelofibrosis.

One new frontier of cancer detection is emerging: metabolomics.

Recent cancer treatment breakthroughs include FDA approvals for zenocutuzumab and durvalumab, and sacituzumab tirumotecan gained breakthrough therapy status. In addition, sonodynamic therapy shows promising results in recurrent glioblastoma, and systemic therapy choices impact brain metastases outcomes, according to new research.

A study of 9,146 patients found no OS difference among first-line CDK4/6 inhibitor combinations for HR+/HER2- metastatic breast cancer, presented at SABCS 2024.

Selinexor with ruxolitinib demonstrated encouraging efficacy with a manageable safety profile in patients with myelofibrosis who were previously treated with ruxolitinib.

Navtemadlin, a novel MDM2 inhibitor, demonstrated potential in treating relapsed or refractory myelofibrosis in the phase 3 BOREAS trial.

Capivasertib combination shows promise in mHSPC vs the placebo combination, LBS-007 received fast track designation, and RP1 plus nivolumab submitted a BLA application. We also cover a retrospective study seeking to identify factors related in delayed care in endometrial cancer and belantamab mafodotin’s BLA application was accepted by the FDA.

The FDA accepted darolutamide’s application for metastatic hormone-sensitive prostate cancer, imatinib is now in liquid form, and ribociclib, combined with an NSAI, showed significant benefit in high-risk, node-negative early-stage breast cancer. Brexu-cel demonstrated CNS remission in relapsed/refractory B-ALL, and a new vaccine shows promise in breast cancer.

The FDA grants approval to revumenib (SNDX-5613) for a subgroup of acute leukemia, and dato-dXd moves into the final stage in NSCLC. We also cover expert updates from the 42nd Annual Chemotherapy Symposium Foundation in CLL, as well as other relevant insights on CML and multiple myeloma treatment.

The 22nd Annual Winter Lung Cancer Conference® will explore advances in neoadjuvant/adjuvant therapies. The FDA has approved Obe-cel for R/R B-ALL, and new treatments in SCLC, lurbinectedin and tarlatamab, show promise. Apalutamide tops enzalutamide in real-world data for mCSPC, and LBL-034 gains orphan drug designation for multiple myeloma.

At the 42nd Annual Chemotherapy Foundation Symposium, Erin Mulvey, MD, discussed the significant progress being made in the treatment of relapsed or refractory follicular lymphoma.

The N-AVD regimen showed improved progression-free survival and lower toxicity than BV-AVD in advanced Hodgkin lymphoma, particularly benefiting patients 60 and older.

Mass spectrometry and machine learning show promise for early cancer detection and prognosis by analyzing metabolic signatures.

October 2024, saw significant FDA actions and clinical trial updates that shaped cancer treatment progress. Highlights include acalabrutinib’s approval for mantle cell lymphoma, T-DXd’s priority review for HER2-low breast cancer, advances in MDS, TNBC, HCC, and perioperative lung cancer research to be discussed at the upcoming 19th Annual New York Lung Cancers Symposium®.

Aumolertinib showed improved PFS in NSCLC and ivonescimab outperforms pembrolizumab in advanced cases. Plus, insights into CAR T-cell therapy and its associated AEs are discussed in relapsed multiple myeloma.

DeepHRD predicted homologous recombination deficiency with greater accuracy than FDA-approved standard molecular tests.

This week’s recap highlights several significant FDA developments. We also cover ongoing successes of pembrolizumab with chemotherapy in NSCLC.

Promising results from the anti–LAG-3/anti–PD-1 combo for melanoma, FDA approval of inavolisib for PIK3CA-mutant breast cancer, significant survival benefits from talazoparib and enzalutamide in prostate cancer, and the launch of the TWINPEAK trial for gastric cancers.

Cologuard Plus test receives FDA approval, understanding genomic profiling leads to advanced personalized care in breast cancer, and a new CAR T therapy is making waves in multiple myeloma.

Test your knowledge on the current pulse of oncology including FDA updates and breaking data with our Targeted Pulse Quiz.

Test your knowledge on the current pulse of oncology including FDA updates and breaking data with our Targeted Pulse Quiz.

Durcabtagene autoleucel shows high response rates in R/R multiple myeloma; olomorasib plus pembrolizumab demonstrates efficacy in KRAS G12C-mutated NSCLC; and the combination of talquetamab, daratumumab, and pomalidomide achieves durable responses. We also cover the FDA’s ODAC vote against checkpoint inhibitors for esophageal cancer.

Evidence suggests that extranodal extension on radiological imaging is a negative prognostic factor in head and neck cancer, but diagnostic criteria and terminology have been unclear.

Debaters Andres Chang, MD, PhD, and Jean Louise Koff, MD, MS, led the verbal battle at the Debates and Didactics in Hematology and Oncology Conference held from July 25 to 28, 2024, in Sea Island, Georgia.

NKT2152 makes strides in RCC, the amivantamab/chemotherapy combination receives approval for EGFR-mutant NSCLC, and experts discuss the future of AML. We also highlight the approval of the 420-mg dose of the trastuzumab biosimilar and offer a focused recap of intriguing data presented at this year’s ESMO Congress.

Test your knowledge on the current pulse of oncology including FDA updates and breaking data with our Targeted Pulse Quiz.

TH17 cells may be a potential biomarker to predict the risk of immune-related adverse events in patients with metastatic melanoma receiving the combination therapy of nivolumab, ipilimumab, and tocilizumab.

Olomorasib with pembrolizumab in the first-line showed a 77% overall response rate in patients with KRAS G12C–mutated metastatic non–small cell lung cancer.

Test your knowledge on the current pulse of oncology including FDA updates and breaking data with our Targeted Pulse Quiz.

Adagrasib bests docetaxel in pretreated KRAS G12C-NSCLC, adding nivolumab to tivozanib in metastatic RCC underwhelms, and T-DXd shows improvement in HER2+ breast cancer with brain metastases.